Professor Li Xiuqin's list, recurrence or metastatic cervical cancer treatment mode change

On July 1, the "Top Ten Progress in the Cancer Field of the Public Public Most Incurities in 2021" was launched in "I do practical practice activities for the masses · Healthy Chinese Oncology Prevention and Control (2022-2023) and" Tumor's Things "column launched The launching ceremony was officially released.

(The above comments are from Professor Li Xiuqin Professor of the Chinese Anti -Cancer Association Gynecology and Cancer Professional Committee, Director of Gynecological Oncology Ward, Shengjing Hospital affiliated to China Medical University)

Paborizumab combined with platinum-containing ± Bearing bead monoclonal Mipido VS placebo combined with platinum-containing ± Bevarzabi-Mipidum Student III Research Keynote-826, which can significantly improve among all the main analysis groups specified in the scheme. OS and PFS.

Among the PD-L1 CPS ≥ 1 crowd, OS (24 months OS 53% VS 41.7%, P <0.001) and PFS (MPFS 10.4 VS8.2 months, P <0.001) and toxic are controllable. It provides further support for the first -line therapy for immunotherapy for advanced, recurrence, and metastatic cervical cancer, and also brings hope to clinicians.

In another way, despite spending expensive medical expenses, some patients extended limited life, and 47%of patients died within 2 years. The cause of cervical cancer is very clear, and there are standard three -level prevention. If more than 90%of the early diagnosis can be cured, it can be cured. From the perspective of health economics, we should strengthen science popularization and do a good job of cervical cancer, and fundamentally change the prognosis of patients with cervical cancer.

- END -